FEBS Letters · 1991 · 70 citations · 11 references
Life SciencesBiochemistryPharmacologyEndocytosisEnzyme MechanismEnzymologyEnzyme InhibitionLysosomal BiochemistryLysosomal DegradationProtein DegradationProteolytic EnzymesProteolytic ProcessingCathepsin ActivityEnzymesLysosomal ProteasesLysosomal Protein DegradationLysosomal ProteolysisProtease InhibitionProteolysis In LysosomesProteolytic Enzyme Activity
A selective inhibitor of cathepsin B, a derivative of E-64 (compound CA-074), and pepstatin-asialofetuin, a potent inhibitor of cathepsin D, were used for an in vivo study of the selective role of these proteinases in lysosomal proteolysis. Administration of compound CA-074 or pepstatinasialofetuin to rats caused only a slight shift of the lysosomal density and no increase in sequestered enzymes in the autolysosomal fraction, although cathepsin B or D activity in the liver was markedly inhibited. These treatments also had little effect on the inhibition of the degradation of endocytosed FITC-labeled asialofetuin. In contrast, leupeptin treatment caused marked inhibition of lysosomal degradation of endogenous and exogenous proteins. These results suggest a small contribution of cathepsins B and D to the initiation of lysosomal proteolysis.
11
Liposome-encapsulated antigens are processed in lysosomes, recycled, and presented to T cells
Clifford V. Harding, David S. Collins, Jan W. Slot et al. · Cell · 1991 · 250 citations